Table 1

Select patient characteristics during baseline or at start of follow-up

ABAADACERETAGOLINFRITTOC
N of episodes13 60810 24129569763177412 75874753332
Demographics
 Age, mean65.5959.9463.4560.8558.2866.2564.963.72
 Female sex, %87.0683.0385.4484.2287.8982.884.486.55
 White race, %77.4765.374.5967.5466.9578.5977.4677.82
 Disabled, %33.0658.8739.7655.5360.9828.6833.3631.75
 Length of follow-up, in days503402260435325558412299
CHD risk factors
 Diabetes, %13.9415.8213.4516.2715.214.1314.8414.11
 Hypertension, %29.6128.3126.4928.3726.0729.6830.0627.85
 Hyperlipidaemia, %22.0820.5322.1620.4720.122.6921.5523.59
Medication use
 DMARD use, %82.0082.8479.7684.2179.1788.1281.9978.87
 Prednisone use/dose, %
  None38.6240.9745.0639.1741.4939.8132.5638.18
  Low (<7.5 mg/day)46.2244.3640.8744.8943.8045.4346.2544.78
  High (≥7.5 mg/day)15.1614.6714.0715.9414.7114.7621.1917.05
 Antihypertensive, %
  ACE inhibitors and ARBs20.1619.6720.3419.718.9819.5920.4520.8
  β Blockers10.779.229.399.819.4610.6510.339.81
 Other antihypertensive29.3527.3726.8228.4025.5129.7531.0828.48
 Statin, %27.7127.1028.1427.8628.7229.725.1027.19
 Prescription non-steroidal anti-inflammatory drugs, %46.9756.0351.1555.1655.4152.5545.0246.22
  • ABA, abatacept; ADA, adalimumab; CER, certolizumab; CHD, coronary heart disease; ETA, etanercept; GOL, golimumab; INF, infliximab; RIT, rituximab; TOC, tocilizumab; DMARD, disease-modifying antirheumatic drug.